CHICAGO, IL — A retrospective study of >24 000 Medicare patients supports something that has previously been demonstrated in rarified clinical-trial populations: namely, that just who is likely to ...
Study Reinforces Clinical and Economic Validity of Expanded Indication for Medtronic CRT-D Devices MINNEAPOLIS and BOSTON – Medtronic, Inc. today announced findings from an economic analysis of the ...
MADIT-CRT is a significant continuation of Boston Scientific’s sponsorship of certain landmark clinical trials such as MADIT, MADIT II, and COMPANION. MADIT-CRT is the largest randomized NYHA Class ...
DUBLIN and BOSTON - MAY 18, 2015 -Medtronic plc (MDT) today announced study results demonstrating that its quadripolar cardiac resynchronization therapy (CRT) system gives physicians more options to ...
Medical device major Medtronic plcMDT recently presented an economic analysis of five-year data on cardiac resynchronization therapy (CRT) devices within its Cardiac Rhythm & Heart Failure (CRHF) ...
Results Provide Evidence Supporting Potential Expansion of Indications for CRT in Symptomatic, Permanent Atrial Fibrillation Patient Population MINNEAPOLIS & SAN FRANCISCO--(BUSINESS WIRE)-- Data ...
Dialysis provider DaVita HealthCare Partners ($DVA) has partnered with Medtronic ($MDT) for a pilot program to study cardiac arrhythmias in end-stage renal disease ...
MINNEAPOLIS & BOSTON--(BUSINESS WIRE)-- Medtronic, Inc. (NYSE: MDT) today announced findings from an economic analysis of the landmark RAFT (Resynchronization / Defibrillation in Ambulatory Heart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback